Loading...

HUMA HUMACYTE INC Capital Structure Changes 8-K Filing

HMCY

HM

HUMACYTE INC

(HUMA)

2025 8-K

Stock Offering Announcement

Clinical Trial Update

Stockholders Meeting

Compliance Regained

NASDAQ Compliance Update

Distribution Agreement Update

Stock Offering Update

Filing Suspension Notice

Sales Agreement

Loan Agreement Details

Agreement Termination

Agreement Termination

Financial Results Announced

Securities Offering

Stock Splits, Stock Buyback...

Financial Statements

Financial Results

Investor Statement

Investor Presentation

Securities Offering

Q3 Financial Results

Clinical Trial Results

Stock Purchase Agreement

FDA Review Delay

Other Special Situation

Annual Meeting of Stockholders

Earnings Report

Earnings Reports

Underwriting Agreement

Investor Presentation

Other Special Situation

Earnings Report

Earnings Reports

Earnings Report

Earnings Report

External Links:

On December 16, 2025, Humacyte, Inc. signed a Sales Agreement allowing the sale of up to $60 million of common stock through TD Securities. The funds will help in commercializing products and further development, though the company is not obligated to sell any shares.

AI Assistant

HUMACYTE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.